Vetstoria vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary Online Appointment Booking Platform
Real-time online appointment booking platform for veterinary practices; Dublin Ireland; raised $8M+; integrates with ezyVet, Provet Cloud, Cornerstone, and Avimark to synchronize 24/7 online bookings with clinic PIMS;
About
Vetstoria is a real-time online appointment booking platform built specifically for veterinary practices, enabling pet owners to book appointments online 24/7 through a clinic's website without phone calls, while giving veterinary teams full control over appointment types, availability, and booking rules. Founded in 2016 and headquartered in Dublin, Ireland, Vetstoria has raised approximately $8 million and grown to serve thousands of veterinary practices globally in Europe, the US, Australia, and Asia, integrating with leading practice management systems to synchronize appointments in real time.\n\nVetstoria's booking platform connects directly to a clinic's veterinary information management system — including ezyVet, Provet Cloud, Cornerstone, Avimark, and others — so bookings made online appear immediately in the practice schedule without staff intervention, and availability shown to clients accurately reflects real-time slot availability. Clinics control which appointment types are bookable online, can set deposit requirements for high-demand slots, and can restrict booking access to existing clients only. Analytics provide data on booking conversion rates, booking source (website, Google, social), and time-of-day patterns.\n\nVetstoria competes with PetDesk, Vetster, and general appointment booking platforms adapted from human healthcare in the veterinary booking space. Its deep PIMS integrations and purpose-built veterinary rules engine — which can handle species-specific booking logic, new patient workflows, and emergency appointment routing — differentiate it from generic online booking tools. The platform helps veterinary practices capture after-hours booking demand, reduce front-desk call volume, and improve the client experience for digitally-oriented pet owners.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.